Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
Provided are methods, combinations and pharmaceutical compositions for treating or preventing an infection in a subject using a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane configured for adhesion of a pathogen that causes said infection. Exemplary infection includes infection caused by a virus, bacterium, fungus, or protozoan.
1. A method of facilitating isolation and removal of a parasitic protozoan that causes malaria from systemic infections comprising:
a) administering to a subject in need a nanoparticle consisting of an inner core comprising a biocompatible or a synthetic material selected from the group consisting of poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid, an outer surface consisting of red blood cell membrane, and a magnetic material encapsulated in said inner core;
b) adhering said nanoparticle to said parasitic protozoan that causes malaria; and
c) isolating and removing said parasitic protozoan that causes malaria from said subject,
wherein said method does not comprise administering quinine to said subject.
2. The method of claim 1 , wherein the magnetic material is iron oxide.
3. The method of claim 1 , wherein a magnetic field is applied in a dialysis device to isolate and remove the parasitic protozoan that causes malaria.
4. The method of claim 1 , wherein the subject is a mammal.
5. The method of claim 4 , wherein the mammal is a human.
6. The method of claim 1 , wherein the inner core supports the outer surface.
7. The method of claim 1 , wherein the nanoparticle has a diameter from about 10 nm to about 10 μm.
8. The method of claim 1 , wherein the nanoparticle substantially lacks hemoglobin of the red blood cell from which the cellular membrane is derived.
9. The method of claim 1 , wherein the inner core of the nanoparticle consists of PLGA and the encapsulated magnetic material, and the outer surface of the nanoparticle consists of a plasma membrane derived from a red blood cell.
10. The method of claim 1 , wherein the nanoparticle substantially lacks immunogenicity to the subject.
11. The method of claim 1 , wherein the parasitic protozoan is P. falciparum, P. malariae, P. ovale, P. vivax or P. knowlesi.
12. The method of claim 11 , wherein the malaria is severe malaria, uncomplicated malaria or cerebral malaria.